Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Annual Report 2023 Download
Sequana Medical is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective.

Listing Prospectus and Related Documents

Listing Prospectus

Prospectus


Article 7:198 juncto articles 7:179, 7:191 and 7:193 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor


2021 Annual Report

2021 Annual Report


2022 Half Year Report

2022 Half Year Report

Press releases

Contact information

Investor Relations:

Email: IR@sequanamedical.com
Tel: +32 498 053579